Quick Dispatch:
Your surmount-osa trial tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-osa trial tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity ships.
Need Help?
Questions about surmount-osa trial tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-osa trial tirzepatide results Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Obesity in your area.
Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?
27.81
In the two SURMOUNT-OSA trials, researchers assessed the efficacy and safety of tirzepatide for the treatment of adults with obstructive sleep apnea and obesity. Full results of both trials and Plain Language
24.84
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial
29.56
SURMOUNT-1 Trial
25.57
01200-X/asset/a888810c-3ccf-4f48-b252-0dfdf720d276/main.assets/gr3_lrg.jpg "Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial")
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
27.61
GLP-1 for Sleep Apnea — What the Data Shows
21.45
Terzapatid in Managing OSA
29.71
